NasdaqCM - Delayed Quote USD

OKYO Pharma Limited (OKYO)

Compare

1.0700

-0.0100

(-0.93%)

At close: 4:00:00 PM EDT

1.0900

+0.02

+(1.87%)

After hours: 4:33:56 PM EDT

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Name	Title	Pay	Exercised	Year Born
Dr. Gary S. Jacob Ph.D.	CEO & Executive Director	588k	--	1947
Mr. Michael Paul Beck	Founder	--	--	1957
Ms. Keeren Shah	Chief Financial Officer	--	--	1975
Dr. Rajkumar Patil Ph.D.	Chief Scientific Officer	--	--	1959

14/15 Conduit St

Floor 4

London, W1S 2XJ

United Kingdom

44 20 7495 2379 https://okyopharma.com

Sector:: Healthcare
Industry:
Full Time Employees:: 3

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events Information Not Available

March 31, 2025 at 12:00 AM UTC